Alternative splicing and cancer metastasis: prognostic and therapeutic applications

被引：34

作者：

Marzese, Diego M. ^{[1
]}

Manughian-Peter, Ayla O. ^{[1
]}

Orozco, Javier I. J. ^{[1
]}

Hoon, Dave S. B. ^{[1
,2
]}

机构：

[1] John Wayne Canc Inst, Dept Translat Mol Med, Santa Monica, CA 90404 USA

[2] John Wayne Canc Inst, Sequencing Ctr, Santa Monica, CA 90404 USA

来源：

CLINICAL & EXPERIMENTAL METASTASIS | 2018年 / 35卷 / 5-6期

基金：

美国国家卫生研究院;

关键词：

Cancer metastasis; Alternative splicing; Epigenetics; Prognostic; Therapeutics; TRACT-BINDING PROTEIN; MESSENGER-RNA; OBLIMERSEN SODIUM; OPEN-LABEL; ANTISENSE OLIGONUCLEOTIDES; DNA METHYLATION; BCL-2; ANTISENSE; BREAST-CANCER; CELL MOTILITY; P53; ISOFORMS;

D O I：

10.1007/s10585-018-9905-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic cells exhibit an extraordinary phenotypic plasticity, not only in adapting to unfamiliar microenvironments but also in surviving aggressive treatments and immune responses. A major source of phenotypic variability is alternative splicing (AS) of the pre-messenger RNA. This process is catalyzed by one of the most complex pieces of cellular molecular regulatory events, the spliceosome, which is composed of ribonucleoproteins and polypeptides termed spliceosome factors. With strong evidence indicating that AS affects nearly all genes encoded by the human genome, aberrant AS programs have a significant impact on cancer cell development and progression. In this review, we present insights about the genomic and epigenomic factors affecting AS, summarize the most recent findings linking aberrant AS to metastatic progression, and highlight potential prognostic and therapeutic applications.

引用

页码：393 / 402

页数：10

共 91 条

[1] Genomic Classification of Cutaneous Melanoma [J].

Akbani, Rehan ;

Akdemir, Kadir C. ;

Aksoy, B. Arman ;

Albert, Monique ;

Ally, Adrian ;

Amin, Samirkumar B. ;

Arachchi, Harindra ;

Arora, Arshi ;

Auman, J. Todd ;

Ayala, Brenda ;

Baboud, Julien ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barnabas, Nandita ;

Bartlett, John ;

Bartlett, Pam ;

Bastian, Boris C. ;

Baylin, Stephen B. ;

Behera, Madhusmita ;

Belyaev, Dmitry ;

Benz, Christopher ;

Bernard, Brady ;

Beroukhim, Rameen ;

Bir, Natalie ;

Black, Aaron D. ;

Bodenheimer, Tom ;

Boice, Lori ;

Boland, Genevieve M. ;

Bono, Riccardo ;

Bootwalla, Moiz S. ;

Bosenberg, Marcus ;

Bowen, Jay ;

Bowlby, Reanne ;

Bristow, Christopher A. ;

Brockway-Lunardi, Laura ;

Brooks, Denise ;

Brzezinski, Jakub ;

Bshara, Wiam ;

Buda, Elizabeth ;

Burns, William R. ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Calderone, Tiffany ;

Cappellini, Giancarlo Antonini ;

Carter, Candace ;

Carter, Scott L. ;

Cherney, Lynn ;

Cherniack, Andrew D. ;

Chevalier, Aaron ;

Chin, Lynda .

CELL, 2015, 161 (07) :1681-1696

[2] Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage [J].

Alsafadi, Samar ;

Houy, Alexandre ;

Battistella, Aude ;

Popova, Tatiana ;

Wassef, Michel ;

Henry, Emilie ;

Tirode, Franck ;

Constantinou, Angelos ;

Piperno-Neumann, Sophie ;

Roman-Roman, Sergio ;

Dutertre, Martin ;

Stern, Marc-Henri .

NATURE COMMUNICATIONS, 2016, 7

[3] Splicing-factor alterations in cancers [J].

Anczukow, Olga ;

Krainer, Adrian R. .

RNA, 2016, 22 (09) :1285-1301

[4] SRSF1-Regulated Alternative Splicing in Breast Cancer [J].

Anczukow, Olga ;

Akerman, Martin ;

Clery, Antoine ;

Wu, Jie ;

Shen, Chen ;

Shirole, Nitin H. ;

Raimer, Amanda ;

Sun, Shuying ;

Jensen, Mads A. ;

Hua, Yimin ;

Allain, Frederic H. -T. ;

Krainer, Adrian R. .

MOLECULAR CELL, 2015, 60 (01) :105-117

[5]

[Anonymous], SCIENTIFICWORLDJOURN

[6] Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing [J].

Araki, Shinsuke ;

Dairiki, Ryo ;

Nakayama, Yusuke ;

Murai, Aiko ;

Miyashita, Risa ;

Iwatani, Misa ;

Nomura, Toshiyuki ;

Nakanishi, Osamu .

PLOS ONE, 2015, 10 (01)

[7] The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome [J].

Avery-Kiejda, Kelly A. ;

Morten, Brianna ;

Wong-Brown, Michelle W. ;

Mathe, Andrea ;

Scott, Rodney J. .

CARCINOGENESIS, 2014, 35 (03) :586-596

[8] Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].

Bedikian, Agop Y. ;

Millward, Michael ;

Pehamberger, Hubert ;

Conry, Robert ;

Gore, Martin ;

Trefzer, Uwe ;

Pavlick, Anna C. ;

DeConti, Ronald ;

Hersh, Evan M. ;

Hersey, Peter ;

Kirkwood, John M. ;

Haluska, Frank G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745

[9] Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial [J].

Beer, Tomasz M. ;

Hotte, Sebastien J. ;

Saad, Fred ;

Alekseev, Boris ;

Matveev, Vsevolod ;

Flechon, Aude ;

Gravis, Gwenaelle ;

Joly, Florence ;

Chi, Kim N. ;

Malik, Zafar ;

Blumenstein, Brent ;

Stewart, Patricia S. ;

Jacobs, Cindy A. ;

Fizazi, Karim .

LANCET ONCOLOGY, 2017, 18 (11) :1532-1542

[10] S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1 [J].

Ben-Hur, Vered ;

Denichenko, Polina ;

Siegfried, Zahava ;

Maimon, Avi ;

Krainer, Adrian ;

Davidson, Ben ;

Karni, Rotem .

CELL REPORTS, 2013, 3 (01) :103-115

← 1 2 3 4 5 6 7 8 9 10 →